Navigation Links
Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer,Patients Treated with Therapy Based on Ratiometric Dosing

tory approval, CPX-1 would be the first commercially-available combination therapy based on Celator's ratiometric dosing drug development platform.

"What we found in this study is that our ratiometric dosing formulation of irinotecan and floxuridine achieved the targeted 1:1 molar ratio that provided synergistic benefits to all patients including those who had been treated previously with irinotecan. Based on these findings, Celator is moving forward with a Phase 2 study for CPX-1 that includes treatment of irinotecan- naïve patients as well as patients who are resistant or refractory to irinotecan," said Arthur Louie, M.D., Celator's chief medical officer.

The ongoing phase 2 study for CPX-1 involves patients with colorectal cancer who will be treated at sites in the U.S. and Canada. For information, visit: www.clinicaltrials.gov/ct/show/NCT00361842?order=1.

ABOUT CELATOR

Celator Pharmaceuticals, Inc., formerly Celator Technologies, Inc., is a privately held biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex, the company's drug ratio technology platform, represents a revolutionary new approach to the development of combination therapies based on the optimal ratio of drug agents to target cancer cells effectively. The company pipeline includes: CPX-1, currently in Phase 2 trials as a treatment option for colorectal cancer; CPX-351, currently in Phase 1 trials as a treatment for leukemia (for information visit www.clinicaltrials.gov/ct/show/NCT00389428?order=2); CPX 571, now positioned to advance to Phase 1 trials and targeting small cell lung cancer; and multiple early stage pre-clinical development programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline
'"/>




Page: 1 2 3

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:8/1/2014)... CHICAGO , Ill. and PALO ALTO, ... ABBV) and Cystic Fibrosis Research, Inc. (CFRI) today announced a ... the cystic fibrosis (CF) community through the CFChef Shares ... September 15, 2014, as part of AbbVie,s CFChef program ... – to encourage patients to maintain a healthy diet ...
(Date:8/1/2014)... Aug. 1, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... pivotal Phase 3 study evaluating ISIS-SMN Rx in ... genetic cause of infant mortality. Isis plans to dose ... few weeks, at which time Isis will earn an ... Idec. The Phase 3 study, ENDEAR, is the first ...
(Date:8/1/2014)... Aug. 1, 2014 Arena Pharmaceuticals, Inc. ... corporate update and reported financial results for the ... "We have continued to see encouraging advancements ... 43% quarter-over-quarter increase in estimated total prescriptions and ... mark," said Jack Lief, Arena,s President and Chief ...
Breaking Medicine Technology:AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 2AbbVie and Cystic Fibrosis Research, Inc. (CFRI) Team Up to Raise Awareness of the Nutritional Needs of CF Patients through the CFChef Shares Program 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 2Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 3Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 4Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-SMN Rx in Infants with Spinal Muscular Atrophy 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 2Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 3Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 4Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 5Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 6Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 7Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 8Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 9Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 10Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2014 Financial Results 11
... Ala., May 7 BioCryst Pharmaceuticals (Nasdaq: BCRX ... first quarter 2009 financial results will be released on Friday, ... a conference call and Web cast at 8:30 a.m. Eastern ... on the Company,s programs. The call will be led ...
... The Abbott RealTi m e HIV-1 Assay and Abbott ... protocol for viral load testing in HIV/AIDS clinical trials sponsored ... This recommendation was made by the Cross-Network Laboratory Focus Group ... HIV/AIDS clinical trials networks. The LFG recently issued a consensus ...
Cached Medicine Technology:BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009 2HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials 2HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials 3
(Date:8/1/2014)... (PRWEB) August 01, 2014 Summer is here, ... most active during the summer, and they can be a ... is ready to help all their customers get rid of ... 3,000 and 6,000 eggs in the summer, which is why ... live in tall grass and woodland areas and carry a ...
(Date:8/1/2014)... Illinois (PRWEB) August 01, 2014 As ... across the country, Ronald E. Johnson, Jr. has been ... by AndroGel and other testosterone medications. Since the Fall ... Johnson, P.S.C. have worked diligently to investigate and prosecute ... pulmonary embolisms, and blood clots as a result of ...
(Date:8/1/2014)... Writing down fears, emotions and the benefits of a ... cancer survivors, according to a study conducted by a ... "The key to developing an expressive writing intervention is ... journal recording facts and events. Writing a journal can ... evidence to determine whether it,s effective or not," said ...
(Date:8/1/2014)... 2014 Growing prevalence of chronic ... reforms are boosting healthcare market growth, although a ... and increasing generic consumption is a major challenge. ... in 2013, having grown at a Compound Annual ... implementation of the Health Transformation Program (Saglikta Donus, ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Hot off the ... destination spa category of the World’s Best Awards by ... a month-long celebration of National Relaxation Day (technically August 15). ... series of MAJOR experts to help guests celebrate relaxation throughout ... it is for health and wellness to carve out time ...
Breaking Medicine News(10 mins):Health News:Tis the Season for Tick Prevention 2Health News:Ron Johnson Named Co-Lead Counsel in Lawsuits for Men Injured by AndroGel and Testosterone 2Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 2Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 3Health News:The Lodge at Woodloch Kicks Off National Relaxation Day with a Month Long Celebration 4
... of remittances shines spotlight on companies engaged in ... those efforts, - Economic issues top ... of origin for the 3x1 and 4+1 programs. - Secure,delivery, seen as most important ... would encourage senders to use companies that ...
... Health and Human Services published an update to its ... and Dependence,which contains revised and improved recommendations to providers ... quitting. The,guideline also confirms that there has never been ... With the release of these new guidelines, smokers ...
... following is a,statement by William V. Corr, Executive ... smoking cessation released today by the U.S. Public,Health ... 45 million,smokers that they have more scientifically proven ... their health than ever before, including safe,and effective ...
... An updated clinical,practice guideline released today by the ... medication treatments that are effective for,helping people quit ... JAMA includes,a commentary that urges clinicians to use ... use of tobacco., Treating Tobacco Use and ...
... results of sub-analyses of dose-titration study and long-term, ... open-label study presented today, WASHINGTON, ... in children, Attention Deficit Hyperactivity Disorder,(ADHD) is now known to be ... lifespan(1). In the US, the overall,prevalence of ADHD in adults is ...
... it helps ease the shock of trauma, study finds ... from post-traumatic stress disorder may ultimately benefit from a ... new research suggests. , The study findings are preliminary. ... a potent way to help PSTD patients through the ...
Cached Medicine News:Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 2Health News:Recipients in Mexico Favor Receiving US-Sent Remittances Through Companies that Contribute to Local Economic Development and Job Creation Projects 3Health News:New Smoking Cessation Guideline Confirms That Now is the Time to Quit Smoking 2Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 2Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 3Health News:New Guidelines Show Smokers Have More Tools to Quit Than Ever, But Elected Officials Must Do More to Help 4Health News:New Evidence Provides Clinicians With Better Tools to Help Smokers Quit 2Health News:New Evidence Provides Clinicians With Better Tools to Help Smokers Quit 3Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 2Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 3Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 4Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 5Health News:OROS(R) Methylphenidate in Adults with ADHD: New Insights 6Health News:Virtual Reality Therapy May Help PTSD Patients 2Health News:Virtual Reality Therapy May Help PTSD Patients 3